Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 16 July 2015, 19:13 HKT/SGT
Share:
    

Source: Uni-Bio Science Group Limited
Uni-Bio Science Group Garners "Pharmaceuticals Award" for Best Innovation at Hong Kong Business Listed Companies Awards

HONG KONG, July 16, 2015 - (ACN Newswire) - Uni-Bio Science Group Limited ("Uni-Bio" or the "Group";HKEx code: 690) has garnered the "Pharmaceuticals Award" for Best Innovation with its Uni-E4 project at the inaugural Hong Kong Business ("HKB") Listed Companies Awards. As the winner under the pharmaceuticals category, the accolade is a strong testimony for the innovation of Uni-Bio's Uni-E4, the Group's proprietary recombinant GLP-1 receptor agonist for the treatment of Type-2 diabetes.

Uni-Bio Science Group Garners "Pharmaceuticals Award" for Best Innovation at Hong Kong Business Listed Companies Awards

Mr. Kingsley Leung, Executive Director of Uni-Bio Science Group, said, "Competing alongside industry peers, we are delighted to be chosen as the winner in the pharmaceuticals category at the HKB Listed Companies Awards. This accolade acknowledges 10 years of hard work by our highly-skilled R&D team in developing Uni-E4. Compared to existing products, Uni-E4 offers a cost-effective alternative to manage diabetes and associated complications - it can effectively reduce blood sugar levels without the increased risk of hypoglycemia, and provide other collateral benefits, such as weight loss and stimulating beta cell regeneration. Therefore, Uni-E4 offers patients, especially overweight diabetics, with a long-term solution for managing their illness. These innovations were instrumental in Uni-Bio garnering this prestigious award. In the future, we will continue fulfilling our commitment to identify and develop new and more efficacious treatment options for our targeted patients in order to better treat their illnesses."


Contact:
Strategic Financial Relations Limited
Veron Ng      Phone: +852 2864 4831   Email: veron.ng@sprg.com.hk
Angelus Lau   Phone: +852 2864 4805   Email: angelus.lau@sprg.com.hk
Caley Chan    Phone: +852 2114 4950   Email: caley.chan@sprg.com.hk
Fax:  +852 2527 1196



Topic: Press release summary
Source: Uni-Bio Science Group Limited

Sectors: Daily Finance
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Uni-Bio Science Group Limited
July 19, 2017 08:23 HKT/SGT
HeungKong Great Health Fund I Injects HK$120 Million into Uni-Bio Science and Becomes its Strategic Shareholder
Feb 27, 2017 09:10 HKT/SGT
Uni-Bio Science's Drugs Officially Reimbursed under the National Reimbursement Drug List
Aug 26, 2016 20:14 HKT/SGT
Uni-Bio Science Group Announces 2016 Interim Results
June 27, 2016 21:06 HKT/SGT
Uni-Bio Science Group Forges Strategic Alliance with China Resources Zizhu for GeneSoft
June 14, 2016 08:06 HKT/SGT
Uni-Bio Science Group Announces 2015 Annual Results
Mar 8, 2016 19:24 HKT/SGT
Uni-Bio Science Completes Phase I Single Ascending Dose (SAD) Tolerability Study of Uni-EPO-Fc for Treatment of Anaemia
Nov 24, 2015 22:55 HKT/SGT
Uni-Bio Science Acquires Global Rights to Type 2 Diabetes Drug Mitiglinide from Jiangsu Hansoh Pharmaceutical Co. Ltd
Sept 8, 2015 18:52 HKT/SGT
Uni-Bio Science Group's Chemical Manufacturing Line in Beijing Passes GMP 2010 Standard
Aug 14, 2015 22:00 HKT/SGT
Uni-Bio Science Group Announces 2015 Interim Results
Aug 3, 2015 10:20 HKT/SGT
Uni-Bio Science Group Announces Positive Phase III Results for Uni-E4 in Type-2 Diabetes
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: